lorazepam has been researched along with clozapine in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 10 (30.30) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Strassburg, CP; Tukey, RH | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Weller, M | 1 |
| Anderson, CB; Cobb, CD; Seidel, DR | 1 |
| Zimbroff, DL | 1 |
| Kingsbury, SJ; Puckett, KM | 1 |
| Klieser, E; Klimke, A | 1 |
| Kanofsky, JF; Konafsky, D; Lindenmayer, JP | 1 |
| Hillard, JR | 1 |
| Hellweg, R; Lausberg, H | 1 |
| Chang, WH; Lane, HY; Su, KP | 1 |
| Böhmer, C; Centelles, JJ; Kinne, RK; Palmada, M | 1 |
| Cherkerzian, S; Cohen, BM; Lange, N; Ma, J; Wager, C; Ye, N | 1 |
| Niedermier, JA | 1 |
| Jiloha, RC; Mendhekar, DN | 1 |
| Durand, M; Forget, K; Grignon, S; Huppert, T | 1 |
| Böker, H; Krähenmann, R; Küchenhoff, B; Schick, M | 1 |
| Bastiampillai, T; Gupta, A; Sani, F; Wang, BZ | 1 |
| Askenazy, F; Drici, M; Lavrut, T; Menard, ML; Yagoubi, F | 1 |
| Huang, TL; Hung, YY; Lin, CC; Tsai, MC | 1 |
| Hadjiphilippou, S; Koychev, I; Lynch, J; MacCabe, J; Whelan, P | 1 |
| Fatemi, MH; Hadjmohammadi, MR; Sheikh, M | 1 |
3 review(s) available for lorazepam and clozapine
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration Schedule; Emergency Services, Psychiatric; Emergency Treatment; Haloperidol; History, 20th Century; Humans; Lorazepam; Olanzapine; Pirenzepine; Psychotic Disorders; Risperidone | 1998 |
30 other study(ies) available for lorazepam and clozapine
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
NMS and lethal catatonia.
Topics: Catatonia; Clozapine; Diagnosis, Differential; Humans; Lorazepam; Neuroleptic Malignant Syndrome | 1992 |
Possible interaction between clozapine and lorazepam.
Topics: Adult; Clozapine; Drug Synergism; Female; Humans; Lorazepam; Male; Middle Aged; Sialorrhea; Sleep Stages | 1991 |
Switching patients from clozapine to risperidone therapy.
Topics: Antipsychotic Agents; Clonazepam; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoxazoles; Lorazepam; Piperidines; Risperidone; Schizophrenia; Substance Withdrawal Syndrome | 1995 |
Effects of fluoxetine on serum clozapine levels.
Topics: Adult; Clonazepam; Clozapine; Drug Interactions; Drug Therapy, Combination; Epilepsies, Myoclonic; Fluoxetine; Humans; Lorazepam; Male; Schizophrenia, Paranoid | 1995 |
Sudden death after intravenous application of lorazepam in a patient treated with clozapine.
Topics: Adult; Clozapine; Death, Sudden; Drug Interactions; Drug Therapy, Combination; Humans; Injections, Intravenous; Lorazepam; Male; Respiratory Insufficiency; Schizophrenia, Paranoid; Sleep Wake Disorders | 1994 |
Relapse in a clozapine responder following lorazepam withdrawal.
Topics: Adult; Clozapine; Drug Therapy, Combination; Humans; Lorazepam; Male; Recurrence; Schizophrenia, Paranoid; Substance Withdrawal Syndrome | 1993 |
["Catatonic dilemma". Therapy with lorazepam and clozapine].
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Diagnosis, Differential; Drug Therapy, Combination; Humans; Lorazepam; Male; Neuroleptic Malignant Syndrome; Schizophrenia, Catatonic | 1998 |
Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects?
Topics: Adult; Anti-Anxiety Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electroencephalography; Humans; Lorazepam; Male; Risperidone; Schizophrenia; Seizures; Substance Withdrawal Syndrome | 1999 |
Effect of benzodiazepines on the epithelial and neuronal high-affinity glutamate transporter EAAC1.
Topics: Amino Acid Transport System X-AG; Animals; Anti-Anxiety Agents; Binding Sites; Carrier Proteins; CHO Cells; Clozapine; Cricetinae; Cricetulus; Diazepam; Epithelial Cells; Glutamate Plasma Membrane Transport Proteins; Glutamic Acid; Ion Transport; Lorazepam; Medazepam; Nerve Tissue Proteins; Neurons; Oocytes; Oxazepam; Recombinant Fusion Proteins; Sodium; Symporters; Xenopus laevis | 1999 |
Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs.
Topics: Amygdala; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Diphenhydramine; Haloperidol; Immunohistochemistry; Injections, Intraperitoneal; Lorazepam; Male; Midline Thalamic Nuclei; Nucleus Accumbens; Olanzapine; Pirenzepine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2003 |
Catatonia in juvenile corrections.
Topics: Adolescent; Catatonia; Clozapine; Humans; Juvenile Delinquency; Lithium; Lorazepam; Male; Prisoners; Treatment Outcome | 2004 |
Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
Topics: Adult; Anti-Anxiety Agents; Antiparkinson Agents; Antipsychotic Agents; Bromocriptine; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Electroconvulsive Therapy; Haloperidol; Humans; Lorazepam; Male; Neuroleptic Malignant Syndrome; Psychotic Disorders; Schizophrenia; Substance Withdrawal Syndrome | 2005 |
Increased left prefrontal activation during staring/mutism episodes in a patient with resistant catatonic schizophrenia: a near infrared spectroscopy study.
Topics: Adult; Attention; Awareness; Catalepsy; Clozapine; Combined Modality Therapy; Dominance, Cerebral; Drug Resistance; Electroconvulsive Therapy; Fixation, Ocular; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lorazepam; Male; Mutism; Oxyhemoglobins; Prefrontal Cortex; Regional Blood Flow; Schizophrenia, Catatonic; Spectroscopy, Near-Infrared; Valproic Acid | 2008 |
[Catatonic dilemma in a schizoaffective patient with combined lithium-risperidone administration].
Topics: Antimanic Agents; Antipsychotic Agents; Brain; Catatonia; Clozapine; Diagnosis, Differential; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electroencephalography; Humans; Hypnotics and Sedatives; Lithium Carbonate; Long-Term Care; Lorazepam; Male; Middle Aged; Psychotic Disorders; Risperidone; Serotonin | 2010 |
Recurrent clozapine and lorazepam withdrawal psychosis with catatonia.
Topics: Adult; Antipsychotic Agents; Catatonia; Clozapine; Disease Management; Female; GABA Modulators; Humans; Lorazepam; Remission Induction; Schizophrenia; Substance Withdrawal Syndrome; Treatment Outcome; Withholding Treatment | 2012 |
[Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms].
Topics: Adolescent; Benzodiazepines; Carbamazepine; Clonazepam; Clozapine; Creatine Kinase; Diagnosis, Differential; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Humans; Lorazepam; Male; Olanzapine; Patient Admission; Psychiatric Status Rating Scales; Psychometrics; Recurrence; Risperidone; Schizophrenia, Catatonic | 2013 |
Relapses and recurrences of catatonia: 30-case analysis and literature review.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Catatonia; Clozapine; Depressive Disorder, Major; Diazepam; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle Aged; Recurrence; Schizophrenia, Catatonic; Young Adult | 2016 |
Sudden-Onset Catatonia Following Clozapine Withdrawal: A Case Report.
Topics: Antipsychotic Agents; C-Reactive Protein; Catatonia; Clozapine; Creatine Kinase; Dantrolene; Drug Monitoring; Drug Substitution; Echocardiography; Humans; Lorazepam; Male; Myocarditis; Neuromuscular Agents; Psychotic Disorders; Treatment Outcome; Troponin; Withholding Treatment; Young Adult | 2016 |
Simultaneous extraction and analysis of clozapine and lorazepam from human plasma using dual solvent-stir bar microextraction with different acceptor phases followed by high-performance liquid chromatography ultra-violet detection.
Topics: Chromatography, High Pressure Liquid; Clozapine; Humans; Liquid Phase Microextraction; Lorazepam; Solvents | 2021 |